Application of a mechanism-based disease systems model for osteoporosis to clinical data

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 2, 2013, Pages 143-156

  Post, Teun M ^a   Schmidt, Stephan ^b,c   Peletier, Lambertus A ^d   De Greef, Rik ^a   Kerbusch, Thomas ^a   Danhof, Meindert ^c  

^a NV ORGANON   (Netherlands)

^b UNIVERSITY OF FLORIDA   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Application to clinical data; Disease systems analysis; Population modeling; Tibolone

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN; PLACEBO; TIBOLONE;

ARTICLE; BONE CELL; BONE DENSITY; BONE TURNOVER; CALCULATION; CELL INTERACTION; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MECHANISM BASED DISEASE SYSTEM MODEL; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROCESS MODEL; PROCESS OPTIMIZATION; SIMULATION; SYSTEM ANALYSIS;

BONE DENSITY; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HIP; HUMANS; LUMBAR VERTEBRAE; MODELS, BIOLOGICAL; NORPREGNENES; OSTEOBLASTS; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 84880697117     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9294-9     Document Type: Article

References (24)

1. Chan PL, Holford NH (2001) Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 41:625-659
2. Post TM, Freijer JI, DeJongh J, Danhof M (2005) Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 22:1038-49
3. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400
4. Schmidt S, Post TM, Peletier LA, Boroujerdi MA, Danhof M (2011) Coping with time scales in disease systems analysis: application to bone remodeling. J Pharmacokinet Pharmacodyn 38:873-900
5. Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ (2004) Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 229:293-309
6. Gallagher JC, Baylink DJ, Freeman R, McClung M (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86:4717-4726
7. Post TM, Cremers SC, Kerbusch T, Danhof M (2010) Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet 49:89-118
8. Berning B, Bennink HJ, Fauser BC (2001) Tibolone and its effects on bone: a review. Climactic 4:120-136
9. Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50:429-50
10. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478
11. Earp JC, DuBois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, Jusko WJ (2008) Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther 326:532-545
12. Marathe DD, Marathe A, Mager DE (2011) Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos 32:471-481
13. Riggs MM, Peterson MC, Gastonguay MR (2012) Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function. J Clin Pharmacol 52:45S-53S
14. Greenspan SL, Emkey RD, Bone HG, Welss SR, Bell NH, Downs RW Jr, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 137:875-883
15. Schmidt S, Post TM, Boroujerdi MA, van Kesteren C, Ploeger BA, Della Pasqua OE, Danhof M (2010) Disease progression analysis: towards mechanism-based models. In: Kimko HC, Peck CC (eds) Clinical trial simulations, 1st edn. Springer, New York, pp 437-459
16. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn 33:313-43
17. Titus L, Jackson E, Nanes MS, Rubin JE, Catherwood BD (1991) 1,25-Dihydroxy vitamin D reduces parathyroid hormone receptor number in ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these receptors: relationship to adenylate cyclase activation. J Bone Miner Res 6:631-637
18. Xie LY, Leung A, Segre GV, Yamamoto I, Abou-Samra AB (1996) Downregulation of the PTH/ PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells. Am J Physiol 270:E654-E660
19. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R (2001) TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20:2254-2272
20. Ducy P, Schinke T, Karsenty G (2000) The osteoblast: a sophisticated fibroblast under central surveillance. Sci Agric 289:1501-1504
21. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764
22. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-57
23. Rachner TD, Hadji P, Hofbauer LC (2012) Novel therapies in benign and malignant bone diseases. Pharmacol Ther 134:338-344
24. Ploeger BA, Holford NH (2009) Washout and delayed start designs for identifying disease modifying effect in slowly progressive diseases using disease progression analysis. Pharm Stat 8:225-38